Drug Profile
Research programme: inositol trisphosphate receptor antagonists - Innovatis Pharma Corporation
Alternative Names: IP 1002ELatest Information Update: 07 Mar 2011
Price :
$50
*
At a glance
- Originator Innovatis Pharma Corporation
- Class
- Mechanism of Action Inositol 1,4,5 trisphosphate receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 12 Jul 2006 Preclinical trials in Cancer in Japan (unspecified route)